Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CART01 in Pediatric R/R B-ALL and NHL
NCT03373071Phase 2Completed
- Start
- Dec 2017
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19-CART01 in B cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL). Started Dec 2017; status: completed.
02
Drugs
CD19-CART01
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03373071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373071.